SCHEMBL13699119

SCHEMBL13699119

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N)cc2)cc1C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
PKM P14618 2/20 0.46
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPK1 P28482 1/20 0.40
LPAR1 Q92633 2/20 0.40
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236455 0.85 PKM (0.63) TAS1R3TAS1R1PKMPOLBMAPK1
SCHEMBL4227928 0.80 PKM (0.69) TAS1R3TAS1R1PKMMAPTMAPK1
SCHEMBL4238162 0.80 PKM (0.52) TAS1R3TAS1R1PKMMAPTMEN1
SCHEMBL4226776 0.76 PKM (0.54) TAS1R3TAS1R1PKMMAPTPOLB
SCHEMBL4240208 0.75 PKM (0.63) TAS1R3TAS1R1PKMPOLBMAPK1
SCHEMBL4229012 0.75 PKM (0.50) TAS1R3TAS1R1PKMMAPTPOLB
SCHEMBL4238062 0.74 MAPK1 (0.43) TAS1R3TAS1R1MEN1KMT2AMAPK1
SCHEMBL4234355 0.73 TAS1R3 (0.57) TAS1R3TAS1R1PKMPOLBMEN1
SCHEMBL4785963 0.73 PKM (0.63) TAS1R3TAS1R1PKMPOLBMAPK1
SCHEMBL4236665 0.73 PKM (0.52) TAS1R3TAS1R1PKMMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R TAS1R3 1436/4885TAS1R1 1073/4885PKM 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.